Clinical Trial Update: Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination chemotherapy plus rituximab in recurrent or refractory non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Nebraska | Conditions: Lymphoma | Phase 2 | Status: COMPLETED